Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Johnson & Johnson Debuts Global Public Health Program

By Andy Szal | April 7, 2016

Johnson & Johnson this week unveiled a new global public health initiative stemming from a new facility in South Africa.

The New Jersey-based pharmaceutical and consumer products giant officially opened its Cape Town operations on Tuesday and detailed plans to help bolster health care across the continent and world.

J&J said that public health staff, as well as representatives from its various companies, will focus on end-to-end health needs including education and training, research and development and manufacturing and distribution.

Company teams will also help translate those efforts into programs that can be executed in communities with local health partners.

The initial phase will focus on HIV, tuberculosis and maternal, newborn and child health in South Africa.

“This is a model based on innovation, collaboration, and local empowerment that aims to address life threatening issues and deliver measurable results to improve outcomes for patients, families and communities, first across Africa, and more globally in the longer term,” J&J Pharmaceuticals Chief Scientific Officer Paul Stoffels said in a statement.

The announcement detailed several new and recent partnerships, including initiatives to prevent the spread of HIV among adolescent girls and to improve health care delivery in low-income areas. The latter effort will begin with 19 clinics before expanding to 50 throughout South Africa.

Johnson & Johnson teams will also work with academic centers and entrepreneurs to establish incubators for medical startups.

The company expects to establish satellite public health offices later this year in Kenya and Ghana and, eventually, expand both its geographic reach and its health targets.

“Ultimately, we’re aspiring to build a healthy world free of disease and our approach here is a potential blueprint for helping us and others succeed against that broader, global goal in the future,” said Chairman and CEO Alex Gorsky.

The program is also expected to increase investment in Johnson & Johnson’s current operations in Africa, which includes three manufacturing plants and more than 1,500 employees.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50